Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 1.39
(9.92%)
SEK 1.39
(9.92%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.11 Million SEK | -32.62% |
| 2022 | 23.92 Million SEK | 93.65% |
| 2021 | 12.35 Million SEK | 53.57% |
| 2020 | 8.04 Million SEK | 36.48% |
| 2019 | 5.89 Million SEK | 2.26% |
| 2018 | 5.76 Million SEK | -3.76% |
| 2017 | 5.98 Million SEK | 35.01% |
| 2016 | 4.43 Million SEK | 92.79% |
| 2015 | 2.3 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 16.11 Million SEK | -32.62% |
| 2023 Q1 | 23.12 Million SEK | -3.31% |
| 2023 Q2 | 23.12 Million SEK | -0.0% |
| 2023 Q4 | 18.11 Million SEK | 0.0% |
| 2023 Q3 | 18.11 Million SEK | -21.66% |
| 2022 Q3 | 23.92 Million SEK | 102.57% |
| 2022 Q1 | 11.81 Million SEK | -4.4% |
| 2022 Q2 | 11.8 Million SEK | -0.01% |
| 2022 FY | 23.92 Million SEK | 93.65% |
| 2022 Q4 | 23.92 Million SEK | 0.0% |
| 2021 FY | 12.35 Million SEK | 53.57% |
| 2021 Q1 | 8.94 Million SEK | 11.22% |
| 2021 Q4 | 12.35 Million SEK | 0.01% |
| 2021 Q3 | 12.35 Million SEK | 38.06% |
| 2021 Q2 | 8.94 Million SEK | -0.01% |
| 2020 Q4 | 8.04 Million SEK | 0.0% |
| 2020 Q2 | 7.49 Million SEK | 4.21% |
| 2020 Q3 | 8.04 Million SEK | 7.31% |
| 2020 Q1 | 7.19 Million SEK | 22.06% |
| 2020 FY | 8.04 Million SEK | 36.48% |
| 2019 Q4 | 5.89 Million SEK | -30.78% |
| 2019 Q2 | 14.66 Million SEK | 147.13% |
| 2019 FY | 5.89 Million SEK | 2.26% |
| 2019 Q1 | 5.93 Million SEK | 2.97% |
| 2019 Q3 | 8.51 Million SEK | -41.94% |
| 2018 Q4 | 5.76 Million SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 FY | 5.76 Million SEK | -3.76% |
| 2018 Q2 | 4.43 Million SEK | 0.0% |
| 2017 Q4 | 5.98 Million SEK | 24.67% |
| 2017 FY | 5.98 Million SEK | 35.01% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q3 | 4.8 Million SEK | 0.0% |
| 2016 FY | 4.43 Million SEK | 92.79% |
| 2016 Q4 | 4.43 Million SEK | 0.0% |
| 2015 FY | 2.3 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | -72.725% |
| Amniotics AB (publ) | 10.54 Million SEK | -52.811% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -264.144% |
| BioArctic AB (publ) | 139.5 Million SEK | 88.447% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 98.971% |
| Genovis AB (publ.) | 98.04 Million SEK | 83.562% |
| LIDDS AB (publ) | 3.75 Million SEK | -329.1% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 87.0% |
| OncoZenge AB (publ) | 1.69 Million SEK | -848.617% |
| Saniona AB (publ) | 86.08 Million SEK | 81.277% |
| Simris Alg AB (publ) | 148.93 Million SEK | 89.179% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 60.555% |
| AcouSort AB (publ) | 10.37 Million SEK | -55.3% |
| Active Biotech AB (publ) | 13.4 Million SEK | -20.276% |
| Camurus AB (publ) | 414.81 Million SEK | 96.115% |
| Cantargia AB (publ) | 54.97 Million SEK | 70.68% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -319.932% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 12.853% |
| Mendus AB (publ) | 51.22 Million SEK | 68.537% |
| Kancera AB (publ) | 17.97 Million SEK | 10.352% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -39.312% |
| Lipum AB (publ) | 7.53 Million SEK | -113.81% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -212.466% |
| NextCell Pharma AB | 13.68 Million SEK | -17.736% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 96.657% |
| Xintela AB (publ) | 14.01 Million SEK | -14.998% |
| Ziccum AB (publ) | 6.38 Million SEK | -152.301% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -17.031% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -583.213% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 15.9% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 77.569% |
| CombiGene AB (publ) | 4.15 Million SEK | -287.801% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 77.338% |
| Intervacc AB (publ) | 21.68 Million SEK | 25.66% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 84.88% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 53.423% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 39.655% |
| Corline Biomedical AB | 6.78 Million SEK | -137.399% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 73.732% |
| Aptahem AB (publ) | 8.99 Million SEK | -79.121% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 65.1% |
| Fluicell AB (publ) | 8.91 Million SEK | -80.785% |
| Biovica International AB (publ) | 34.76 Million SEK | 53.643% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -38.13% |
| Abliva AB (publ) | 16.78 Million SEK | 3.957% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 92.49% |
| 2cureX AB (publ) | 2.93 Million SEK | -449.131% |
| I-Tech AB | 16.2 Million SEK | 0.543% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.641% |
| Cyxone AB (publ) | 4.69 Million SEK | -243.353% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -20.926% |
| Biosergen AB | 5.08 Million SEK | -216.952% |
| Nanologica AB (publ) | 79.32 Million SEK | 79.683% |
| SynAct Pharma AB | 51.83 Million SEK | 68.907% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -102.755% |
| BioInvent International AB (publ) | 90.45 Million SEK | 82.182% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -210.244% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 91.125% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -798.384% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -26.467% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -121.997% |